See your projected weight regain risk, timeline, and metabolic changes — plus a personalised plan to maintain your results after stopping Ozempic, Wegovy, or tirzepatide.
12-month weight regain projection
—
lbs projected regain in 12 months
Based on STEP 1 extension study data
Weight at 3 months
—
lbs projected
Weight at 6 months
—
lbs projected
Calories to maintain
—
daily at current weight
Projected regain timeline
Your personalised maintenance strategies
Projections use STEP 1 extension trial data adjusted for individual lifestyle factors. Individual results vary significantly. Not medical advice — consult your provider before stopping any medication.
Based on your regain risk
Consider staying on a maintenance dose instead
Stopping GLP-1 carries significant regain risk. Compounded semaglutide from licensed providers starts at $146/month — making long-term maintenance more affordable than branded alternatives.
Sponsored · Compounded GLP-1 not FDA-approved as finished drug · Prices confirmed at intake
About this calculator
What the research says about stopping GLP-1
The STEP 1 extension study provides the most comprehensive data on what happens after stopping semaglutide. Participants who stopped medication at week 68 were followed for an additional 52 weeks. By week 120, participants had regained two-thirds of their original weight loss — an average of 11.6% of body weight gained back in the first 20 weeks alone.
This regain is not a failure of willpower. It reflects the biological role of GLP-1 as a chronic treatment for obesity — when the medication stops, the underlying hormonal dysregulation that drives overeating reasserts itself.
Key finding: The weight regain after stopping semaglutide follows a predictable curve — fastest in the first 3 months, slower from months 3 to 12. This is why the first 90 days after stopping are the most critical period for dietary intervention.
Factors that affect regain rate
Duration on medication
Patients who spent more time on GLP-1 treatment — especially 12 months or more — tend to maintain better results post-stopping than shorter-duration users. Longer treatment allows more time to build sustainable dietary habits that persist after the appetite-suppression effect ends.
Dietary habits built during treatment
Patients who consciously built new eating habits during treatment — reduced portion sizes, lower ultra-processed food intake, structured meal timing — show meaningfully better post-stop maintenance than those who relied entirely on medication-driven appetite suppression without modifying underlying behaviours.
Muscle mass maintained during treatment
Patients who preserved lean muscle mass through protein intake and resistance training have higher resting metabolic rates, making weight maintenance easier after stopping. Significant muscle loss during treatment creates a metabolic disadvantage that makes regain more likely.
The cost alternative: maintenance dosing
An increasing number of prescribers offer maintenance dosing — a lower dose after reaching goal weight rather than full cessation. Compounded semaglutide from licensed providers at $146/month makes long-term maintenance doses financially viable for many patients who cannot afford branded Wegovy long-term.
Frequently asked questions
When you stop taking semaglutide, appetite returns to pre-treatment levels as GLP-1 receptor stimulation ceases. A landmark 2022 study found that participants regained an average of two-thirds of their lost weight within one year of stopping semaglutide. The weight regain is not a failure of willpower — it reflects the biological reality that GLP-1 medications treat obesity as a chronic condition, and stopping treatment allows the underlying condition to reassert itself.
Weight regain after stopping semaglutide begins within the first 2 to 4 weeks as appetite regulation normalises. The STEP 1 extension study showed the fastest regain occurs in the first 3 months after stopping, with participants regaining an average of 11.6% of body weight in the first 20 weeks. After this initial rapid phase, regain slows. By 68 weeks after stopping, the average total regain was two-thirds of the original weight loss.
Most people regain significant weight after stopping GLP-1 medications, but approximately 10 to 20% of patients maintain most of their weight loss after stopping — typically those who used the treatment period to build sustainable dietary habits, increase physical activity, and add muscle mass. Key factors that predict better maintenance: strong protein intake established during treatment, regular resistance training continued after stopping, gradual dose reduction rather than abrupt cessation, and addressing underlying behavioural drivers of overeating.
The most evidence-supported approach to stopping GLP-1 without major regain is gradual tapering rather than abrupt cessation, combined with strong dietary and exercise habits. Taper dose over 4 to 8 weeks rather than stopping suddenly. Maintain protein intake at 0.7 to 1.0g per pound of body weight. Continue resistance training. Calculate your new maintenance calorie intake based on your reduced body weight. Consider whether a lower maintenance dose is possible rather than complete cessation.
Yes. Some prescribers offer maintenance dosing strategies where patients taper to a lower dose after reaching goal weight, rather than stopping entirely. Compounded semaglutide from licensed telehealth providers starting from $146 per month makes long-term maintenance financially viable for patients who cannot afford branded Wegovy long-term. This is a prescriber-specific decision based on individual response and tolerance.